Dr. Andy Whittamore, a GP and clinical lead at Asthma and Lung UK, shed light on four chronic lung conditions that tend to ...

No link was found between Competitive Bidding Program implementation and changes in supplemental oxygen use or clinical ...

The Texas Tech University Health Sciences Center is offering a new treatment for patients suffering from severe chronic ...

Verona Pharma’s Ohtuvayre has a solid market entry, but its valuation is high. Read why VRNA stock remains a buy for ...

Benralizumab is more effective than prednisolone in treating eosinophilic exacerbations in patients with asthma and COPD.

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

In a cohort of adults with chronic obstructive pulmonary disease (COPD), receiving fluticasone-umeclidinium-vilanterol was ...

For the past 10 years, medications and inhalers began to help less and less with Rose Walsh’s breathing problems. Battling ...

But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.

PAH is a rare condition in children, but is often fatal if left untreated, and protocols for pediatric patients have not been ...

Verona Pharma (VRNA) stock in focus as company reports early sales for Q4 and 2024 thanks to its lung disease therapy ...

Budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol ...